2021
Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial CancerSex Hormones and Insulin in Endometrial Cancer Recurrence
Merritt MA, Strickler HD, Hutson AD, Einstein MH, Rohan TE, Xue X, Sherman ME, Brinton LA, Yu H, Miller DS, Ramirez NC, Lankes HA, Birrer MJ, Huang GS, Gunter MJ. Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial CancerSex Hormones and Insulin in Endometrial Cancer Recurrence. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 719-726. PMID: 33622671, PMCID: PMC8026669, DOI: 10.1158/1055-9965.epi-20-1613.Peer-Reviewed Original ResearchConceptsEndometrial cancer recurrenceSex hormonesEndometrial cancerProgesterone receptorCancer recurrenceInsulin/insulin-like growth factor axisRecurrence riskInsulin-like growth factor (IGF) axisInsulin-like growth factorGynecologic Oncology GroupProgression-free survivalEndometrial adenocarcinoma patientsIGF-binding proteinsFuture clinical trialsGrowth factor axisConfidence intervalsIR/IGF1RAdjuvant therapyER positivityIGFBP-3Oncology GroupProspective cohortAdenocarcinoma patientsPretreatment specimensSerum concentrations
2018
A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma
Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecologic Oncology 2018, 149: 585-591. PMID: 29572027, PMCID: PMC5986604, DOI: 10.1016/j.ygyno.2018.03.050.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian carcinomaSerous ovarian carcinomaIL-6Ovarian cancerOvarian carcinomaE-cadHigh-grade serous ovarian adenocarcinomaEarly-stage ovarian cancerROC analysisEarly detectionMajority of patientsLethal gynecologic malignancyStage ovarian cancerOvarian cancer patientsBenign gynecologic pathologyNon-cancer controlsSerous ovarian adenocarcinomaEffective cancer screeningSerous ovarian cancerMultiple biomarker panelsFour-marker panelHigh differential gene expressionGynecologic malignanciesCA 125IL-1raInsulin‐like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma
Van Arsdale AR, Arend RC, Cossio MJ, Erickson BK, Wang Y, Doo DW, Leath CA, Goldberg GL, Huang GS. Insulin‐like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. Cancer Medicine 2018, 7: 616-625. PMID: 29455465, PMCID: PMC5852335, DOI: 10.1002/cam4.1335.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkers, TumorCarcinosarcomaFemaleHumansInsulin-Like Growth Factor IIPrognosisRace FactorsUterine NeoplasmsConceptsProgression-free survivalOverall survivalUterine carcinosarcomaHigh IGF2IGF2 levelsMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelRace-stratified multivariable analysesProportional hazards regression modelsReduced progression-free survivalInsulin-like growth factor 2 expressionRacial disparitiesIndependent risk factorEarly-stage diseaseRisk of deathHazards regression modelsPoor prognostic biomarkerGrowth factor 2 expressionFactor 2 (Nrf2) protein expressionFactor 2 expressionBlack womenAdjuvant therapyWhite patientsMultivariable analysisBlack race
2010
Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer
Huang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER, Goldberg GL, Smith HO, Horwitz SB. Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer. Clinical Cancer Research 2010, 16: 2999-3010. PMID: 20404007, PMCID: PMC2887721, DOI: 10.1158/1078-0432.ccr-09-3233.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, PhytogenicBiomarkers, TumorCell Line, TumorCell ProliferationDisease-Free SurvivalDrug Resistance, NeoplasmFemaleGene Knockdown TechniquesHumansInsulin-Like Growth Factor IIOvarian NeoplasmsPaclitaxelPhosphorylationPrognosisProto-Oncogene Proteins c-aktPyrimidinesPyrrolesReceptor, IGF Type 1RNA, Small InterferingSignal TransductionConceptsEpithelial ovarian tumorsInsulin-like growth factorDisease-free survivalOvarian carcinoma cellsOvarian tumorsTaxol resistancePathway inhibitionIGF2 expressionOvarian cancerCarcinoma cellsExact testReduced disease-free survivalHuman epithelial ovarian tumorsCandidate prognostic biomarkerDrug-resistant ovarian carcinoma cellsUpregulation of IGF2Fisher's exact testIGF2 protein expressionOvarian cancer cellsDrug-resistant phenotypeHigh IGF2 expressionIGF receptor inhibitorsPathologic factorsTaxol-resistant cell linesCox regression